559 related articles for article (PubMed ID: 25858810)
1. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
2. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
4. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
5. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
6. Using Novel Agents and Stem Cell Transplantation to Optimally Manage Immunoglobulin Light Chain Amyloidosis.
Gertz MA
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1339-40. PubMed ID: 25899453
[No Abstract] [Full Text] [Related]
7. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
[TBL] [Abstract][Full Text] [Related]
9. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
10. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
13. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
14. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
[TBL] [Abstract][Full Text] [Related]
15. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
[TBL] [Abstract][Full Text] [Related]
16. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
17. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
[TBL] [Abstract][Full Text] [Related]
18. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
20. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
Landau H; Smith M; Landry C; Chou JF; Devlin SM; Hassoun H; Bello C; Giralt S; Comenzo RL
Leukemia; 2017 Jan; 31(1):136-142. PubMed ID: 27560108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
